Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: Lessons learned from Seattle, Washington

References

• Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry. 2014;13(2):153–160.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Bucello C, Mathers B. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011;106(1):32–51.
   PubMed Web of Science ®Google Scholar
• Reinhart M, Scarpati LM, Kirson NY, Patton C, Shak N, Erensen JG. The economic burden of abuse of prescription opioids: a systematic literature review from 2012 to 2017. Appl Health Econ Health Policy. 2018;16(5):609.
   PubMed Web of Science ®Google Scholar
• Fisher WH, Clark R, Baxter J, Barton B, O’Connell E, Aweh G. Co-occurring risk factors for arrest among persons with opioid abuse and dependence: implications for developing interventions to limit criminal justice involvement. J Subst Abuse Treat. 2014;47(3):197–201.
   PubMed Web of Science ®Google Scholar
• Iheanacho T, Stefanovics E, Rosenheck R. Opioid use disorder and homelessness in the Veterans Health Administration: the challenge of multimorbidity. J Opioid Manag. 2018;14(3):171–182.
   PubMedGoogle Scholar
• Health and Human Services. HHS Acting Secretary Declares Public Health Emergency to Address National Opioid Crisis. 2017; https://www.hhs.gov/about/news/2017/10/26/hhs-acting-secretary-declares-public-health-emergency-address-national-opioid-crisis.html. Accessed July 18, 2019.
   Google Scholar
• Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949–958.
   PubMed Web of Science ®Google Scholar
• Ling W, Hillhouse M, Ang A, Jenkins J, Fahey J. Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction. 2013;108(10):1788–1798.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207.
   PubMed Web of Science ®Google Scholar
• Pierce M, Bird SM, Hickman M, et al. Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England. Addiction. 2016;111(2):298–308.
   PubMed Web of Science ®Google Scholar
• Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.
   PubMed Web of Science ®Google Scholar
• SAMHSA. Buprenorphine. 2016; https://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine. Accessed January 20, 2019.
   Google Scholar
• Martin SA, Chiodo LM, Bosse JD, Wilson A. The next stage of buprenorphine care for opioid use disorder. Ann Intern Med. 2018;169(9):628–635.
   PubMed Web of Science ®Google Scholar
• AlderksCE. Trends in the Use of Methadone, Buprenorphine, and Extended-release Naltrexone at Substance Abuse Treatment Facilities: 2003-2015 (Update). In: Center for Behavioral Health Statistics and Quality SAaMHSA, ed. Rockville, MD. 2017.
   Google Scholar
• Wu LT, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;169:117–127.
   PubMed Web of Science ®Google Scholar
• Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90–96.
   PubMed Web of Science ®Google Scholar
• Glick SN, Tinsley J, Hood JE, Klein K. Needle Exchange Program. In: HIV/AIDS Epidemiology Report 2017. Vol Volume 86.: HIV/AIDS Epidemiology Unit, Public Health – Seattle & King County and the Infecious Disease Assessment Unit, Washington State Department of Health.; 2017:59–62.
   Google Scholar
• Knudsen HK, Abraham AJ, Oser CB. Barriers to the implementation of medication-assisted treatment for substance use disorders: the importance of funding policies and medical infrastructure. Eval Program Plann. 2011;34(4):375–381.
   PubMed Web of Science ®Google Scholar
• Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55–63.
   PubMed Web of Science ®Google Scholar
• National Health Care for the Homeless Council. Medication-Assisted Treatment: Buprenorphine in the HCH Community. 2016; https://www.nhchc.org/policyadvocacy/reform/nhchc-health-reform-materials/
   Google Scholar
• Kourounis G, Richards BD, Kyprianou E, Symeonidou E, Malliori MM, Samartzis L. Opioid substitution therapy: lowering the treatment thresholds. Drug Alcohol Depend. 2016;161:1–8.
   PubMed Web of Science ®Google Scholar
• Hawk M, Coulter RWS, Egan JE, et al. Harm reduction principles for healthcare settings. Harm Reduct J. 2017;14(1):70.
   PubMedGoogle Scholar
• Fox AD, Sohler NL, Frost T, Lopez C, Cunningham CO. Development and evaluation of a community-based buprenorphine treatment intervention. Harm Reduct J. 2017;14(1):23.
   PubMedGoogle Scholar
• Bachhuber MA, Thompson C, Prybylowski A, Benitez J, Mazzella S, Barclay D. Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program. Subst Abus. 2018;39(2):167–172.
   PubMed Web of Science ®Google Scholar
• Heroin and Prescription Opiate Addiction Task Force Final Report and Recommendations. 2016; http://www.kingcounty.gov/∼/media/depts/community-human-services/behavioral-health/documents/herointf/Final-Heroin-Opiate-Addiction-Task-_Force-Report.ashx?la=en. Accessed September 5, 2017.
   Google Scholar
• Killeen TK, Back SE, Brady KT. Implementation of integrated therapies for comorbid post-traumatic stress disorder and substance use disorders in community substance abuse treatment programs. Drug Alcohol Rev. 2015;34(3):234–241.
   PubMed Web of Science ®Google Scholar
• Simon CB, Tsui JI, Merrill JO, Adwell A, Tamru E, Klein JW. Linking patients with buprenorphine treatment in primary care: predictors of engagement. Drug Alcohol Depend. 2017;181:58–62.
   PubMed Web of Science ®Google Scholar
• Alford DP, LaBelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171(5):425–431.
   PubMedGoogle Scholar
• Hser YI, Evans E, Grella C, Ling W, Anglin D. Long-term course of opioid addiction. Harv Rev Psychiatry. 2015;23(2):76–89.
   PubMed Web of Science ®Google Scholar
• Stancliff S, Joseph H, Fong C, Furst T, Comer SD, Roux P. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations. J Addict Dis. 2012;31(3):278–287.
   PubMed Web of Science ®Google Scholar
• Hersh D, Little SL, Gleghorn A. Integrating buprenorphine treatment into a public healthcare system: the San Francisco Department of Public Health's office-based Buprenorphine Pilot Program. J Psychoactive Drugs. 2011;43(2):136–145.
   PubMed Web of Science ®Google Scholar
• Cunningham CO, Roose RJ, Starrels JL, Giovanniello A, Sohler NL. Prior buprenorphine experience is associated with office-based buprenorphine treatment outcomes. J Addict Med. 2013;7(4):287–293.
   PubMed Web of Science ®Google Scholar
• Monico LB, Mitchell SG, Gryczynski J, et al. Prior experience with non-prescribed buprenorphine: role in treatment entry and retention. J Subst Abuse Treat. 2015;57:57–62.
   PubMed Web of Science ®Google Scholar
• Davidson R. Prochaska and DiClemente's model of change: a case study? Br J Addict. 1992;87(6):821–822.
   PubMedGoogle Scholar